Entera Bio Ltd.

ENTX

IL0011429839

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-05 pm EST			5-day change	1st Jan Change
1.230 ^USD	-5.38%		-18.54%	-36.60%

Mar. 04	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis	CI
Mar. 04	Entera Bio submits streamlined phase 3 protocol to initiate registrational program for EB613 in postmenopausal women with osteoporosis	RE

Entera Bio appoints former Pfizer executive Geno J. Germano as chairman of the board ahead of key milestones

Published on 02/09/2026 at 11:01 am EST

Reuters

Latest news about Entera Bio Ltd.

Mar. 04	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis	CI
Mar. 04	Entera Bio submits streamlined phase 3 protocol to initiate registrational program for EB613 in postmenopausal women with osteoporosis	RE
Feb. 27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
Feb. 11	Entera Bio announces open market purchases of company stock by board members	RE
Feb. 09	Entera Bio appoints former Pfizer executive Geno J. Germano as chairman of the board ahead of key milestones	RE
Feb. 09	Entera Bio Ltd: Geno J. Germano appointed as chairman of Entera Bio	RE
Feb. 09	Entera Bio Ltd. Announces Board Changes, Effective February 4, 2026	CI
Feb. 04	Opko Health and Entera Bio expand partnership to advance first-in-class oral long acting PTH tablet for patients with hypoparathyroidism	RE
Feb. 04	OPKO Health, Entera Bio Expand Partnership for Oral Hypoparathyroidism Treatment	MT
Feb. 04	OPKO Health, Inc. and Entera Bio Ltd. Expand Partnership to Advance First-In-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism	CI
Feb. 04	Entera Bio Ltd. Announces Board Changes, Effective February 1, 2026	CI
Dec. 22	Entera Bio Ltd. Announces New Data Supporting Further Development of A Proprietary First-In-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)	CI
Nov. 14	Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-16	Entera Bio Ltd. to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society Annual Meeting	CI
25-09-15	Entera Bio Reports Positive PK Data for First-In-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress	CI

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Employees

Sector

Biotechnology & Medical Research

More about the company